182 related articles for article (PubMed ID: 38726789)
1. PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.
Kumar M; Ashok SA; Datusalia AK; Khatik GL
Med Chem; 2024 May; ():. PubMed ID: 38726789
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.
Sodhi RK; Singh N; Jaggi AS
Naunyn Schmiedebergs Arch Pharmacol; 2011 Aug; 384(2):115-24. PubMed ID: 21607645
[TBL] [Abstract][Full Text] [Related]
3. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.
Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB
Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration.
Durai P; Beeraka NM; Ramachandrappa HVP; Krishnan P; Gudur P; Raghavendra NM; Ravanappa PKB
Curr Neuropharmacol; 2022; 20(5):893-915. PubMed ID: 34751120
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
7. PPARs in Alzheimer's Disease.
Kummer MP; Heneka MT
PPAR Res; 2008; 2008():403896. PubMed ID: 18645613
[TBL] [Abstract][Full Text] [Related]
8. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
[TBL] [Abstract][Full Text] [Related]
9. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
Luo R; Su LY; Li G; Yang J; Liu Q; Yang LX; Zhang DF; Zhou H; Xu M; Fan Y; Li J; Yao YG
Autophagy; 2020 Jan; 16(1):52-69. PubMed ID: 30898012
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-128 knockout inhibits the development of Alzheimer's disease by targeting PPARγ in mouse models.
Liu Y; Zhang Y; Liu P; Bai H; Li X; Xiao J; Yuan Q; Geng S; Yin H; Zhang H; Wang Z; Li J; Wang S; Wang Y
Eur J Pharmacol; 2019 Jan; 843():134-144. PubMed ID: 30412727
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
Agarwal S; Yadav A; Chaturvedi RK
Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
[TBL] [Abstract][Full Text] [Related]
12. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer's Disease.
Kotha S; B S; Kulkarni VM; S RS; B HK; R H
J Biomol Struct Dyn; 2021 Apr; 39(6):2210-2229. PubMed ID: 32216605
[TBL] [Abstract][Full Text] [Related]
13. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha.
Combs CK; Bates P; Karlo JC; Landreth GE
Neurochem Int; 2001; 39(5-6):449-57. PubMed ID: 11578780
[TBL] [Abstract][Full Text] [Related]
14. PPARs in the brain.
Heneka MT; Landreth GE
Biochim Biophys Acta; 2007 Aug; 1771(8):1031-45. PubMed ID: 17569578
[TBL] [Abstract][Full Text] [Related]
15. Functional role of lipoprotein receptors in Alzheimer's disease.
Jaeger S; Pietrzik CU
Curr Alzheimer Res; 2008 Feb; 5(1):15-25. PubMed ID: 18288927
[TBL] [Abstract][Full Text] [Related]
16. The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders.
Matrisciano F; Pinna G
Adv Exp Med Biol; 2023; 1411():513-535. PubMed ID: 36949324
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma.
Vallée A; Lecarpentier Y
Front Neurosci; 2016; 10():459. PubMed ID: 27807401
[TBL] [Abstract][Full Text] [Related]
18. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
[TBL] [Abstract][Full Text] [Related]
19. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
